Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carparts.Com Inc (PRTS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Carparts.Com IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Carparts.Com Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Carparts.Com Inc trades at $8.61 (market cap $66.42M), while Regeneron Pharmaceuticals Inc trades at $744.35 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 1146.3× Carparts.Com Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

PRTSREGN
Market Cap
$66.42M$76.14B
Volume
40,287500,239
Sector
Consumer CyclicalHealth
52-Week High
$10.00$852.03
52-Week Low
$3.88$557.73
Typical Hold Time
45 Days107 Days
Enterprise Value
$79.39M$70.85B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carparts.Com Inc

CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.

The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PRTS
0% Buy100% Sell
Avg holding period · 45 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

Top news

Latest headlines on both assets

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →